Significant Progress Made as Numinus-Sponsored PRIME Study on Psilocybin-Assisted Psychotherapy for Opioid, Stimulant and/or Alcohol Use Disorders Enters Pre-Implementation Stage Numinus Wellness (OTC:LKYSD) and Syreon Corporation, a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. The study will contribute to a growing body of research to inform larger randomized controlled trials for these indications. The study will take place in Vancouver and will enroll 30 individuals with opioid, stimulant and/or alcohol use disorders. Syreon is leading the trial as Clinical Research Organization (CRO) with Numinus as the trial sponsor.